Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20341662 | 1.00 | THRB (0.55) | THRBCYP3A4CYP2C9CYP2C19MAPK1 | |
| SCHEMBL14407001 | 1.00 | THRB (0.55) | THRBCYP3A4CYP2C9CYP2C19MAPK1 | |
| SCHEMBL2690796 | 0.93 | THRB (0.49) | THRBCYP3A4CYP2C9CYP2C19MAPK1 | |
| SCHEMBL13661273 | 0.91 | THRB (0.47) | THRBCYP3A4CYP2C9CYP2C19MAPK1 | |
| SCHEMBL6520242 | 0.86 | — | — | |
| SCHEMBL1823080 | 0.86 | — | — | |
| SCHEMBL14628363 | 0.86 | — | — | |
| SCHEMBL27957554 | 0.83 | THRB (0.51) | THRBCYP3A4CYP2C9CYP2C19MAPK1 | |
| SCHEMBL2682746 | 0.82 | THRB (0.42) | THRBCYP3A4CYP2C9CYP2C19MAPK1 | |
| SCHEMBL4943057 | 0.79 | THRB (0.49) | THRBCYP3A4CYP2C9CYP2C19MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024249268-A2 | COMPOSITIONS AND METHODS FOR EXTRACTING LITHIUM FROM AN AQUEOUS SOLUTION | ENERGY EXPLORATION TECHNOLOGIES, INC. (US) | 2024-12-05 | — | — | WO | claimed |
| WO-2024249270-A1 | REAGENT COMPOSITIONS, APPARATUS AND METHODS FOR EXTRACTING LITHIUM FROM MIXED SALTS | ENERGY EXPLORATION TECHNOLOGIES, INC. (US) | 2024-12-05 | — | — | WO | claimed |
| US-10562991-B2 | Developer, pattern forming method, and electronic device manufacturing method | FUJIFILM CORPORATION (JP) | 2020-02-18 | — | — | US | claimed |
| CN-119678921-A | Cyclohexene derivative with attraction effect on carpiotosia borer as well as preparation method and application thereof | 华东理工大学 | 2025-03-25 | — | — | CN | disclosed |
| WO-2024249270-A1 | REAGENT COMPOSITIONS, APPARATUS AND METHODS FOR EXTRACTING LITHIUM FROM MIXED SALTS | ENERGY EXPLORATION TECHNOLOGIES, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024249268-A2 | COMPOSITIONS AND METHODS FOR EXTRACTING LITHIUM FROM AN AQUEOUS SOLUTION | ENERGY EXPLORATION TECHNOLOGIES, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-118076767-A | Method and formulation for producing an optical metal oxide layer | 默克专利有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4318629-A1 | PRIMER FOR POWER STORAGE DEVICE ELECTRODES, COMPOSITION FOR FORMING PRIMER LAYER, ELECTRODE FOR POWER STORAGE DEVICES, AND SECONDARY BATTERY | AGC INC. (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20230420686-A1 | PRIMER FOR POWER STORAGE DEVICE ELECTRODE, COMPOSITION FOR FORMING PRIMER LAYER, ELECTRODE FOR POWER STORAGE DEVICE, AND SECONDARY BATTERY | AGC Inc. (JP) | 2023-12-28 | — | — | US | disclosed |
| US-11826351-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230372298-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-11-23 | — | — | US | disclosed |
| US-4094606-A | Xerographic system employing waveguide addressing and modulating apparatus | XEROX CORPORATION (US) | 1978-06-13 | — | — | US | disclosed |
| US-4077700-A | Waveguide addressing and modulating method and apparatus | XEROX CORPORATION (US) | 1978-03-07 | — | — | US | disclosed |
| US-4005032-A | Liquid crystalline composition having mixed cholesteric-nematic properties | XEROX CORPORATION (US) | 1977-01-25 | — | — | US | disclosed |
| US-3989355-A | Electro-optic display system | XEROX CORPORATION (US) | 1976-11-02 | — | — | US | disclosed |
| US-3972588-A | Imaging method | XEROX CORPORATION (US) | 1976-08-03 | — | — | US | disclosed |
| US-3952193-A | Imaging method with U.V. excitation of liquid crystal | XEROX CORPORATION (US) | 1976-04-20 | — | — | US | disclosed |
| US-3947183-A | LIQUID CRYSTAL DISPLAY SYSTEM | XEROX CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
| US-3938880-A | Spherulitic liquid crystalline texture | XEROX CORPORATION (US) | 1976-02-17 | — | — | US | disclosed |
| US-3936640-A | Imaging system | XEROX CORPORATION (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826351-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | THRB 3342/4885CYP3A4 3571/4885CYP2C9 2791/4885 |
| US-20230372298-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | THRB 3342/4885CYP3A4 3571/4885CYP2C9 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.